Keywords: Cardiometabolic diseases; atherosclerosis; microRNA; fatty liver disease
 

"MicroRNA-26b plays a major regulatory role in cardiometabolic diseases"
 

This dissertation investigated the role of the microRNA molecule miR-26b in diseases related to the heart and metabolism, known as cardiometabolic diseases (CMDs). CMDs, such as atherosclerosis and fatty liver disease, are major causes of illness and death worldwide but are not yet fully understood. The research was divided into three parts: the influence of miR-26b on platelet function, atherosclerosis, and fatty liver disease. The study found that miR-26b plays a protective role in these diseases. For example, disabling miR-26b in mice led to more severe disease symptoms, such as larger blood clots and worsened liver inflammation. The research suggests that miR-26b could potentially be used in new treatments for cardiovascular diseases.  

Click here for the live stream.